Rahul D. Ballal, Director at Enliven Therapeutics, Inc. (ELVN), sold 20,840 shares at $28.17 ($587K) on 2024-10-08, disclosed to the SEC on 2024-10-10.
Scheduled sale ($587k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.17 | 10,420 | $294K | 50.0% |
| 2 | $28.17 | 10,420 | $294K | 50.0% |
| Total | $28.17 avg | 20,840 | $587K | 100% |
| Filing → |
| ELVN | SELL | 2024-04-08 | $133K | — | Filing → |
| ELVN | SELL | 2024-04-03 | $124K | — | Filing → |
| ELVN | SELL | 2024-03-22 | $509K | — | Filing → |